Evidence map›Paper›PMID 32562695›Full record

ArticleBiochimica et biophysica acta. Biomembranes2020

Discovery and mechanistic characterization of a structurally-unique membrane active peptide.

Shivani Bansal, Wan-Chih Su, Madhu Budamagunta, Wenwu Xiao, Yousif Ajena, Ruiwu Liu, John C Voss, Randy P Carney, Atul N Parikh, Kit S Lam

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta. Biomembranes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. My Perspective on OBOC Combinatorial Technology.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shivani BansalDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, United States of America; Department of Chemistry, University of California, Davis, United States of America.
Wan-Chih SuDepartment of Chemistry, University of California, Davis, United States of America; Department of Biomedical Engineering, University of California, Davis, United States of America.
Madhu BudamaguntaDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, United States of America.
Wenwu XiaoDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, United States of America.
Yousif AjenaDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, United States of America.
Ruiwu LiuDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, United States of America.
John C VossDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, United States of America.
Randy P CarneyDepartment of Biomedical Engineering, University of California, Davis, United States of America.
Atul N ParikhDepartment of Biomedical Engineering, University of California, Davis, United States of America.
Kit S LamDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, United States of America; Department of Chemistry, University of California, Davis, United States of America. Electronic address: kslam@ucdavis.edu.
University of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Therapeutic Targeting Agents for Ovarian CancerR01CA115483 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI LAM, KIT S · 2005 to 2019
$5.5M
Targeting nanotherapeutics against murine and feline oral cancerR01EB012569 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2011 to 2019
$4.2M
The rodent eye as a non-invasive window for understanding cancer nanotherapeuticsU01CA198880 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2015 to 2019
$2.9M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA115483NCI NIH HHS U01 CA198880NIBIB NIH HHS R01 EB012569
6 · The paper itself

Abstract

Membrane active peptides (MAPs) have gained wide interest due to their far reaching applications in drug discovery and drug delivery. The search for new MAPs, however, has been largely skewed with bias selecting for physicochemical parameters believed to be important for membrane activity, such as alpha helicity, cationicity and hydrophobicity. Here we carry out a search-and-find strategy to screen a 100,000-membered one-bead-one-compound (OBOC) combinatorial peptide library for lead compounds, agnostic of those physicochemical constraints. Such a synthetic strategy also permits expansion of our peptide repertoire to include unnatural amino acids. Using this approach, we discovered a structurally unique lead peptide LBF14, a linear 14-mer peptide, that induces gross morphological disruption of membranes, irrespective of membrane composition. Further, we demonstrate that the unique insertion mechanism of the peptide, visualized by spinning disc confocal microscopy and further analyzed by electron paramagnetic resonance measurements, may be the cause of this large scale membrane deformation. We also demonstrate the robustness, reproducibility, and potential application of this technique to discover and characterize new membrane active peptides that display activity by local insertion and subsequent allosteric effects leading to global membrane disruption.

Indexed as

Drug DiscoveryAnimalsElectron Spin Resonance SpectroscopyMembrane ProteinsMiceMice, Inbred BALB CMicroscopy, FluorescencePeptidesProtein ConformationMembrane ProteinsPeptidesCombinatorial libraryGiant unilamellar vesiclesInterfacial activityMembrane active peptideMembrane activityMembrane dynamics

Identifiers

PMID32562695
PMCPMC7478859
OpenAlexW3036351422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.